EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Risk Assessment Considerations in the Cell Therapy Supply Chain
Volume 10 Issue 5

Risk Assessment Considerations in the Cell Therapy Supply Chain

The cell therapy industry is advancing at significant pace, with these novel therapies providing curative treatments to patients who previously had little hope of sur...
Continue Reading →
A Clinical Study to Evaluate the Efficacy and Safety of Instavit®
Volume 10 Issue 5

A Clinical Study to Evaluate the Efficacy and Safety of Instavit®

Instavit® instant energy is a doctor formulated oral spray supplement contains an ideal blend of caffeine and B vitamins to help improve alertness and fight everyday ...
Continue Reading →
Europe

Targeted drugs for advanced cancer move from specialist units to community setting

Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA muta...
Continue Reading →
Europe

Immunotherapy may become new first line treatment in some metastatic colorectal cancers

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaki...
Continue Reading →
news

FDA approves asthma indication for Dupixent® (dupilumab)

Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent asthma, ...
Continue Reading →
Europe

Polyganics Initiates First-in-Human Trial of LIQOSEAL®, its Innovative Approach for Dural Closure

Groningen, The Netherlands, October 22, 2018 / B3C newswire / -- Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable ...
Continue Reading →
Europe

Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma

Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of ...
Continue Reading →
Europe

Nanobiotix: Positive Phase II / III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris, presented first-in-class NBTXR3 positive Phase II/III results during...
Continue Reading →
news

Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer – The primary endpoint was met

Orion and Bayer have completed the phase III clinical trial (ARAMIS) of darolutamide, the novel oral androgen receptor antagonist for the treatment of patients with n...
Continue Reading →
Europe

Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival

Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including o...
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18